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Methyltransferases and demethylases are emerging targets for epigenetic therapy.Wigle et al. (2010) present
a new assay for the enzyme inhibition of methyltransferases and demethylases based on selective enzymatic
cleavage of unmethylated versus methylated peptides and their subsequent electrophoretic separation.The therapeutic potential of drugs that
influence posttranslational modifications
of histones is vast, as there are many
diseases, especially cancer, that have
been linked to aberrant gene expression
patterns or deregulated histone modifica-
tions. Therefore, it is of particular impor-
tance to find the inhibitors of histone-
modifying enzymes in order to target
these diseases; usually, as a first step in
epigenetic drug discovery, biochemical
in vitro assays are the tools of choice.
Wigle et al. (2010) have presented a new
assay for studying enzyme and inhibition
kinetics of methyltransferases and deme-
thylases that is expanding the possible
ways to explore these enzymes. Histone
methylation and demethylation are two
of the most interesting posttranslational
modifications, which may also occur on
nonhistone substrates. Histone methyla-
tion is mediated by histone methyltrans-
ferases and is involved in several impor-
tant processes, such as heterochromatin
formation and maintenance, X chromo-
some inactivation, transcriptional regula-
tion, DNA repair, RNA maturation, and
genomic imprinting (Spannhoff et al.,
2009). Histones can be methylated either
on lysine or on arginine residues. Depend-
ing on the site of methylation, lysine
methylation can be linked either to tran-
scriptional activation or repression. Meth-
ylation on H3K4 (throughout the text,
specific histone residues will be labeled
as follows: histone H3 lysine 4, H3K4,
etc.), H3K36, and H3K79, for example, is
considered to be activating, whereas
methylated H3K9, H3K27, and H4K20
are regarded as repressive marks (Martin
and Zhang, 2005). The loss of trimethyla-
tion at H4K20 is a general hallmark ofhuman cancer, together with the loss of
acetylation at H4K16 (Fraga et al., 2005).
Histone methyltransferases are by far
not restricted to histones as substrates.
Besides histone proteins, many other
targets for histone methyltransferases
have been identified thus far—e.g., the
tumor suppressor protein p53. Both lysine
and arginine residues within p53 are
methylated by different enzymes. To
give an example, the lysine methyltrans-
ferase G9a (KMT1C), also chosen by the
authors as a representative methyltrans-
ferase in the newly established assay,
has recently been shown to dimethylate
p53 on K373. This was correlated with
inactivity of p53 (Huang et al., 2010). Its
impact on apoptotic processes, as well
as its overexpression in various cancer
types, suggests that G9a is a putative
oncogene (Huang et al., 2010). Demethy-
lation of methylated lysines is catalyzed
by LSD1, which is able to demethylate
H3K4 me1/me2 (Shi et al., 2004) and
JmjC-domain-containing enzymes that
are able to turn over trimethylated lysines
(Xiang et al., 2007). LSD1 colocalizes with
the androgen receptor and participates in
androgen-receptor activation. Thus, the
inhibitors of LSD1 activity could be valu-
able drugs that affect androgen-receptor
functions (Metzger et al., 2005).
As for probing enzyme activity and the
potency of inhibitors, some assays are
already available for methyltransferases
(reviewed in Spannhoff et al. [2009]),
which are now complemented by Wigle
et al. (2010) with their newly presented
assay. For methyltransferases, the incor-
poration of radioactivity by radioactively
labeled cofactor S-adenosyl-[methyl-3H]
can be measured. The protocols usingChemistry & Biology 17, July 30, 2010radioactivity are sensitive, but they bear
the disadvantage of hazards for the
user and additional measures and costs
regarding waste disposal. Also for a high
throughput, specialized equipment is
necessary (Scintillation proximity assay).
Furthermore, the turnover of SAM to
S-adenosyl homocysteine (SAH) can be
used to detect methyltransferase activity.
In a corresponding assay, the byproduct
SAH is hydrolyzed to S-ribosylhomocys-
teine and adenine by a nucleosidase.
The formed adenine is then hydrolyzed
by a second enzyme to homoxanthine.
This is accompanied by a decrease in
absorbance at 265 nm that can be moni-
tored. The low wavelength is a disadvan-
tage due to a high risk for compound
interference. Another drawback is the
need for several enzymes in the proce-
dure. A different method to detect SAH
is to use the ThioGlo reagent that is
based on detecting reactive sulfhydryl
groups. The caveat of this assay is that
thiols are also present in many buffers,
especially those for methyltransferases,
and therefore this assay might not always
be eligible. A further possibility to con-
duct a homogeneous assay is to use
an AlphaScreen (Amplified Luminescent
Proximity Homogeneous Assay) setup
(Quinn et al., 2010).
Antibody-based assays, such as the
one in AlphaScreen approaches, are
a good tool for the determination of
enzyme activity and inhibition properties
of different compounds. These assays
can be set up like a construction kit, using
peptide or native substrates, a number of
primary antibodies for the respective
target, and also different secondary anti-
bodies for the different readout methods.ª2010 Elsevier Ltd All rights reserved 677
Figure 1. Screening Assay for Lysine Methyltransferases and
Demethylases
Methylation-sensitive proteolysis leads to fluorescent peptides with different
size and hence mass-to-charge ratio. These can be separated by capillary
electrophoresis.
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in vitro methyltransferase ac-
tivity, a heterogeneous assay
using biotinylated histone
peptide as a substrate was
presented by our group
(Spannhoff et al., 2007). The
peptide is immobilized on
streptavidine-coated micro-
titer plates. The methylation
can be recognized by using
antibodies directed against
the methyl mark transferred
by the respective methyl-
transferase. Subsequent in-
cubation with an europium-
labeled secondary antibody
allows the measurement of
time-resolved fluorescence
(TRF) to detect the methyla-
tion level. These heteroge-
neous assays are rather time
demanding compared with
the homogeneous assays.The newly published assay shows
potential for drug screening, as it is minia-
turized and can be easily automated. It is
based on capillary electrophoresis, in
which charged molecules are separated
through their charge and size. As a
disadvantage, specialized and expensive
equipment (Caliper Ez Reader II) is
necessary for performing the assay and
fluorescence-labeled peptides have to
be used. As methylated and unmethy-
lated peptides do not differ in their charge,
they normally would be difficult to sepa-
rate. To solve this problem, Wigle et al.
(2010) used a protease (Endo-LysC),
which is sensitive to the methylation
mark and does not digest methylated
peptides (see Figure 1). This is the aspect
of the paper with the greatest relevance
for a broader research community. The678 Chemistry & Biology 17, July 30, 2010 ª2methylation-sensitive proteolytic cleav-
age enables testing of the activity ofmeth-
yltransferases and demethylases as long
as a suitable peptide substrate is known
and available. Because of the good solu-
bility of the peptides and because it is
not necessary to immobilize substrates,
enzyme kinetics can be studied better,
as with antibody-based procedures,
which is another benefit of this method.
The assay was set up for a lysine methyl-
transferase G9a and the demethylase
LSD1 so far, but it could be used as well
for other lysine methyltransferases. With
a suitable protease, application for argi-
nine methyltransferases such as PRMT1
should be possible as well. The cleavage
reaction might also be exploited in other
assay formats such as AlphaScreen,
fluorescence energy transfer (FRET), or010 Elsevier Ltd All rights reservedfluorescence polarization (FP)
methods, similar, for exam-
ple, to an established proto-
col for sirtuins (Milne et al.,
2007).
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